Cellebrite DI (CLBT) Asset Writedowns and Impairment (2024 - 2026)

Cellebrite DI has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $1.1 million in Q2 2026.

• On a quarterly basis, Asset Writedowns and Impairment fell 1.12% year-over-year to $1.1 million in Q2 2026; TTM through Jun 2026 was $4.5 million, a 9.11% decrease from a year earlier, with the FY2025 full-year figure at $4.6 million, down 14.06% from the prior year.
• Asset Writedowns and Impairment was $1.1 million for Q2 2026 at Cellebrite DI, roughly flat from $1.1 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $1.4 million in Q4 2024, with the low at $1.1 million in Q1 2026.
• Average Asset Writedowns and Impairment over 3 years is $1.2 million, with a median of $1.2 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Asset Writedowns and Impairment slipped 19.86% in 2025, then fell 1.12% in 2026.
• Over 3 years, Asset Writedowns and Impairment stood at $1.4 million in 2024, then retreated by 19.86% to $1.2 million in 2025, then fell by 8.95% to $1.1 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $1.1 million (Q2 2026), $1.1 million (Q1 2026), and $1.2 million (Q4 2025), per Business Quant data.